Chile Nephrology Stents Catheter Market Size & Outlook, 2026-2034
Chile Nephrology Stents Catheter Market Insights
- As per Reed Intelligence insights, the Chile Nephrology Stents Catheter Market stood at USD 34.07 Million in 2025 and is anticipated to grow to USD 64.29 Million by 2034.
- The Chile market is expected to advance at a CAGR of 7.34% from 2026 through 2034.
- In 2025, Ureteral Stents accounted for the highest share of the Product Type market size.
- During the forecast period, Ureteral Access Sheaths is set to register the highest growth, making it the most lucrative Product Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Chile represented 0.7% of the overall global Nephrology Stents Catheter Market size.
- United States is projected to lead the global Nephrology Stents Catheter Market size by 2034.
- Across LATAM, Brazil is anticipated to hold the dominant position in market size by 2034.
- Colombia is forecasted to expand at the fastest pace in LATAM, attaining USD 68.95 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 34.07 Million |
| Market Size In 2034 | USD 64.29 Million |
| Largest segment | Ureteral Stents |
| Units | Revenue in USD Million |
| CAGR | 7.34% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Chile Nephrology Stents Catheter Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ureteral Stents | XX.x | XX.x | XX.x | 13.72 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nephrostomy Catheters | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dialysis Catheters | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ureteral Access Sheaths | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Chile Nephrology Stents Catheter Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kidney Stone Management | XX.x | XX.x | XX.x | 14.09 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Chronic Kidney Disease Access Management | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Urinary Obstruction | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Post-Surgical Drainage | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Chile Nephrology Stents Catheter Market End User 2026-2034 (USD Million)
| End User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 14.33 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dialysis Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.